Butyrate
Best-in-class: Butyrate
The primary short-chain fatty acid that fuels colon cells — the postbiotic your gut bacteria normally make from fiber, supplied directly.
Butyrate quick facts
| Suggested dose | As directed (tributyrin is better-absorbed and less odorous). |
| How often | Daily |
| Who it's for | Gut-barrier, colon health and microbiome support. |
The shortcut when the fiber route is not working — either because intake is low, or because the bacteria that ferment it are missing, which is the more common and less obvious problem. Tributyrin is the better-tolerated form; sodium-potassium butyrate has the odor problem that makes people quit. Genuinely one of the more mechanistically justified gut supplements.
How Butyrate actually works
A short-chain fatty acid and the preferred fuel of colonocytes — they oxidize it in preference to glucose, which is unusual and tells you how central it is. Beyond fuel it is a histone deacetylase inhibitor, which is how it regulates tight-junction protein expression and induces regulatory T-cells. Normally it is produced by bacterial fermentation of fiber; supplementing supplies it directly.
Where to get Butyrate
Find Butyrate on iHerb →What it is, why it recurs, and where this fits — free to read.
The evidence for Butyrate
Graded by what exists behind each claim.
✅ Clinically validated
- Supports colon-cell health, gut-barrier integrity and a calm inflammatory tone; studied in IBS/IBD contexts.
- Primary energy source for colonocytes.
📊 Correlative data
- The strongest observational case in this category, and it is not about the supplement. Populations eating high-fiber diets produce far more butyrate in the colon and show lower rates of colorectal cancer and inflammatory bowel disease — one of the most consistent associations in nutritional epidemiology. Whether swallowing butyrate reproduces what fermenting fiber produces *in situ* is the open question.
🧪 Theoretical / extrapolated benefits
- Metabolic and gut-brain benefits are emerging; tributyrin forms improve delivery.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Butyrate actually does
Butyrate is a four-carbon fatty acid that the colon runs on. Isolated human colonocytes were offered n-butyrate, glucose and glutamine together and butyrate accounted for 73% of oxygen consumption in the ascending colon and 75% in the descending colon Roediger 1980. Not a supporting nutrient. Three quarters of the fuel of a cell layer that renews itself every few days, supplied from outside the body by bacteria.
The transport step is named, and it decides everything downstream. Butyric acid has a pKa near 4.8, so in an acidic stomach it is uncharged and crosses membranes by simple diffusion; at colonic pH it is an anion and needs a carrier. Two exist on the apical membrane of the colonocyte: the proton-coupled monocarboxylate transporter MCT1, and the sodium-coupled monocarboxylate transporter SMCT1, the product of SLC5A8 Gupta 2006. Both face the LUMEN. This cell is built to eat from the gut side, which is the fact that makes an oral capsule a delivery problem rather than a dosing question.
The second job is epigenetic, and it is a real drug mechanism. Butyrate inhibits histone deacetylase activity Davie 2003. Blocking HDACs leaves histones hyperacetylated, opens chromatin at specific promoters and drives p21(Waf1/Cip1), a cyclin-dependent kinase inhibitor that arrests the cell cycle. That is the same class of action as a licensed oncology drug, produced by a bacterial waste product at millimolar concentrations your colon reaches every day.
The paradox, and its resolution, is the best thing on this shelf. Butyrate stimulates the proliferation of normal colonocytes and inhibits the proliferation of cancerous ones — the same molecule, opposite signs, cells that touch each other. The reason is metabolic. A normal colonocyte oxidizes butyrate to acetyl-CoA and burns it, so little accumulates in the nucleus and it acts as food. A cancerous colonocyte has switched to the Warburg effect, ferments glucose instead, does not oxidize butyrate, and lets it build up to concentrations where it functions as an HDAC inhibitor Donohoe 2012. Whether butyrate is fuel or drug is decided by which metabolic program the cell in front of it is running.
Where it comes from normally, in numbers. Short-chain fatty acids measured in human intestinal contents run to 131 ± 9 mmol/kg in the caecum and 80 ± 11 mmol/kg in the descending colon, against 13 ± 6 mmol/kg in the terminal ileum Cummings 1987. Butyrate is a minority of that molar total, but the shape of the gradient is the point: this is a molecule that exists at tens of millimoles per kilogram in the large bowel and at almost nothing upstream of it.
Cell, rodent, human — and where it stops
Cells. The 73% and 75% oxygen-consumption figures come from colonocytes isolated from seven ascending and seven descending human colon specimens Roediger 1980; the HDAC inhibition and the p21 induction are cultured-cell work Davie 2003; the fuel-versus-drug switch was established in normal and cancerous colonocytes side by side Donohoe 2012. That is an unusually solid mechanistic floor for a supplement.
Now do the arithmetic that decides whether a capsule touches any of it. A review that set out specifically to fix a butyric acid dose concluded that the current standard supplement doses of 150–300 mg represent between 1.5–3% and 15–30% of the reported daily demand Banasiewicz 2020. Read that twice. At best you are adding under a third of what your colon already handles; at worst you are adding one part in sixty-six.
Then ask where it goes, because unprotected it never arrives. Sodium butyrate released in the stomach is protonated and lipid-soluble, and anything surviving into the jejunum meets MCT1 and SMCT1 Gupta 2006. The terminal ileum holds 13 ± 6 mmol/kg of total short-chain fatty acid against 131 in the caecum Cummings 1987 — the small bowel does not accumulate these molecules, it clears them. An uncoated dose is a systemic dose.
And a systemic dose cannot reach the colonocyte's apical surface, which is where the transporters are. Portal blood carries 375 ± 70 µmol/L of short-chain fatty acid, the hepatic vein 148 ± 42 and peripheral blood 79 ± 22 Cummings 1987. The liver strips roughly six tenths of the portal load in a single pass, and what is left in the systemic circulation sits two to three orders of magnitude below the lumen it is supposed to be refilling. Swallowing butyrate and expecting colonic concentrations is pushing water uphill.
The human pharmacokinetic data exist, and they are oncology data. Thirteen patients took tributyrin at 50–400 mg/kg/day by mouth; peak plasma butyrate ranged from 0 to 0.45 mM, with grade 3 nausea, vomiting and myalgia at the top Conley 1998. Twenty more took 150–200 mg/kg three times daily and reached a median butyrate concentration of 52 µM Edelman 2003. For a 70 kg adult, 200 mg/kg three times daily is about 42 grams of tributyrin a day. A supplement capsule holds a few hundred milligrams. The doses that produced a measurable blood level were on the order of a hundred times a capsule, and even they produced micromolar plasma against a millimolar lumen.
Which leaves the trials that did work, and what they actually measured. Sixty-six patients with irritable bowel syndrome took microencapsulated sodium butyrate for 12 weeks; pain on defecation fell significantly by week 4, with urgency and bowel habit improving by week 12 Banasiewicz 2013. Forty-nine patients with inflammatory bowel disease — 19 Crohn's, 30 ulcerative colitis — plus 18 healthy volunteers took it for two months, and the reported effect was a shift in the community: more butyrate-capable Lachnospiraceae in ulcerative colitis and more Butyricicoccus in Crohn's Facchin 2020. The obstacle is that both are disease populations, and the second suggests the mechanism is not the fuel at all — it is a signal that makes the community produce more of its own.
Butyrate — which form, and does it matter
Sodium butyrate: do the mass balance before you read the label. Sodium butyrate has a formula weight of about 110, of which sodium is roughly 21%. So a 500 mg dose is about 395 mg of butyrate anion and about 105 mg of sodium. Three capsules a day is a third of a gram of added sodium that nothing on the front of the bottle mentions, and the calcium and magnesium butyrate salts move that burden onto a different cation rather than removing it.
Tributyrin is denser and quieter, and that is its real argument. Tributyrin is glycerol with three butyrates esterified to it, formula weight about 302, of which roughly 87% by mass is butyric acid equivalents. It has no free carboxylic acid, so it does not smell of rancid butter and does not deliver a cation. It is also the form with human pharmacokinetics attached Conley 1998 Edelman 2003 — which is exactly why the numbers in those studies are so unflattering to a capsule.
The coating question is the one nobody frames correctly. A standard enteric polymer dissolves above roughly pH 5.5–7, which happens in the duodenum and jejunum. That protects the dose from gastric acid and then releases it directly into the segment carrying the transporters that will absorb it Gupta 2006. Enteric coating solves the stomach and does nothing about the actual problem, which is another five or six meters of absorption downstream.
Microencapsulation in a fat matrix is a different claim from enteric coating, and it is the one with the trials. Both published clinical results here used microencapsulated sodium butyrate rather than a plain or simply enteric-coated capsule Banasiewicz 2013 Facchin 2020: butyrate dispersed in a lipid that releases slowly along the length of the bowel rather than dumping at one pH. If a label says only “enteric”, it is not the preparation the trials used, and there is no published head-to-head between the two.
Tributyrin does not solve delivery either, and the page should say so. An ester is hydrolyzed by lipases in the small intestine and by cellular esterases, which liberates butyrate exactly where absorption is fastest. Tributyrin's honest selling points are palatability, no cation load and higher mass efficiency. Reaching the colon is not one of them.
What would have to be true, and how you would know it was not
1. The read-out is symptoms on a four-to-eight week clock, and the trials say when. Pain on defecation separated at week 4 and urgency and bowel habit at week 12 Banasiewicz 2013. So predict nothing informative before week 4, a first change between weeks 4 and 8, and treat anything that happens in the first fortnight as noise. A colonocyte's fuel status is not a sensation, so there is nothing to feel on day three.
2. The prediction that cuts against the product, and it is the arithmetic. Predict that an uncoated, non-microencapsulated product does nothing measurable at all, at any dose you would swallow. A standard 150–300 mg dose is between 1.5% and 30% of daily demand before absorption is even considered Banasiewicz 2020, and the oncology work needed tens of grams of tributyrin to reach 52 µM in blood Edelman 2003. If a plain capsule produces a dramatic effect in week one, the most likely explanation is the excipient, the diet change that started the same week, or the condition's own cycle.
3. Fecal short-chain fatty acids are the honest laboratory test, and they should mostly not move. If the mechanism were direct fuel delivery, fecal butyrate would rise with the dose. If instead the mechanism is what the IBD study saw — a community shifting toward butyrate-producing taxa Facchin 2020 — then fecal butyrate should rise slowly, over weeks, and should keep rising for a while after the capsules stop. Those two predictions differ in shape and in persistence, and one stool panel before and two after would separate them.
4. Blood markers: predict flat, and know which one could surprise you. Predict hs-crp and cbc are unchanged — systemic butyrate exposure from a capsule sits far below what the liver already clears from portal blood every hour Cummings 1987. The one number worth watching is on the cmp: sodium, in anyone taking three or more sodium butyrate capsules a day on a restricted-sodium regimen. Retest at 12 weeks.
What nobody has tested yet
Nobody has measured colonic butyrate in a human after a supplement. The entire argument for this product is that swallowed butyrate raises luminal butyrate at the colonocyte, and the measurement — colonic aspirate or stool water butyrate before and after a defined dose of a defined preparation — has never been published. Everything on this page is inference from a transport map Gupta 2006 and a concentration gradient Cummings 1987 because the direct experiment does not exist.
Nobody has run microencapsulated against enteric-coated against tributyrin. Three delivery strategies, three different physical assumptions, two of them with clinical trials attached to only one form Banasiewicz 2013 Facchin 2020 and one with pharmacokinetics from oncology Conley 1998. A four-arm trial with a stool butyrate endpoint would sort the whole category in twelve weeks.
Nobody has tested it in people who are well. Both clinical populations were symptomatic — irritable bowel syndrome Banasiewicz 2013 and inflammatory bowel disease Facchin 2020. What a daily HDAC-inhibiting molecule does to a healthy colonic epithelium over years is unmeasured, and the fuel-versus-drug switch says the answer depends on the metabolic state of each cell Donohoe 2012. That is a reason to want the study, not a reason to assume it would be reassuring.
And nobody has tested the obvious comparator. Fermentable fiber makes butyrate in the right place, in the right amounts, for pennies. A trial of oral butyrate against a matched dose of a fiber that yields butyrate, with the same endpoints, has not been run — and it is the only trial that could tell you whether the postbiotic shortcut is worth anything over the substrate.
Butyrate — its own safety story, not its category's
The dose-limiting toxicity is known, because oncology found it. Tributyrin at up to 400 mg/kg/day produced grade 3 nausea, vomiting and myalgia Conley 1998. That is 28 grams a day in a 70 kg adult and nobody is taking that from a supplement bottle — which is the point: the ceiling of this molecule sits so far above supplement doses that supplement doses are safe and, by the same arithmetic, small.
The cation is the real everyday consideration. Sodium butyrate is about a fifth sodium by mass, so a three-capsule day adds roughly 0.3 g of sodium. In heart failure, in resistant hypertension and in chronic kidney disease that is a number worth knowing, and it is printed nowhere on the front of a bottle sold for gut health.
The mechanistic caution nobody states: this is an HDAC inhibitor. Butyrate's epigenetic action is not a metaphor Davie 2003, and its direction of effect on a colonocyte depends on whether that cell oxidizes it Donohoe 2012. In a healthy colon the local concentration is already millimolar every day and has been for your whole life, so a supplement is a small addition to a large existing exposure. That is genuinely reassuring for the colon and it says nothing at all about a tissue that normally never sees the molecule.
The honest limit is duration and population. Twelve weeks in 66 people with irritable bowel syndrome Banasiewicz 2013 and two months in 49 people with inflammatory bowel disease Facchin 2020. That is the whole safety file for the microencapsulated form, it covers a season, and none of it was in healthy adults taking it indefinitely, which is who buys it.
Sources read for this page
- Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980 · PMID 7429343
- Cummings JH. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987 · PMID 3678950
- Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003 · PMID 12840228
- Donohoe DR. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 2012 · PMID 23063526
- Gupta N. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci 2006 · PMID 16375929
- Banasiewicz T. Determination of butyric acid dosage based on clinical and experimental studies - a literature review. Prz Gastroenterol 2020 · PMID 32550943
- Conley BA. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998 · PMID 9533530
- Edelman MJ. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother Pharmacol 2003 · PMID 12736763
- Banasiewicz T. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013 · PMID 22738315
- Facchin S. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil 2020 · PMID 32476236
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Urgency, stool form and lower abdominal discomfort. This is a postbiotic rather than a fiber — you are swallowing the end product instead of feeding its production — so symptoms are the honest target, because the fuel status of a colonocyte is not something anyone can perceive.
- How long before it means anything: Four to eight weeks. The barrier and inflammatory-tone claims are structural rather than fast, and short courses of this get abandoned long before the mechanism could have shown anything.
- What will fool you: The population evidence people buy this on is about high-fiber diets producing butyrate in the colon, not about swallowing it — so butyrate being protective is not evidence that this capsule is. Tributyrin also carries far less of the odor problem, so a change of form changes adherence and can look like a change in effect.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Butyrate — safety & side effects
- The smell is the main complaint — sodium butyrate has a distinctive rancid-butter odor, and burping it is unpleasant. GI upset otherwise.
- Well tolerated in the trials. No established significant drug interactions.
- Tributyrin and coated forms exist largely to solve the smell. Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Butyrate in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Butyrate
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | Anemia is the commonest sign of a gut absorbing badly |
| Ferritin | Iron is the first thing malabsorption takes |
| Vitamin B12 | The second thing, and the one with permanent consequences |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Separates inflammatory bowel disease from IBS |
The Gut Health & Absorption panel covers these in one order — 11 markers, $208.80 with the discount applied.
Check results you already have → · All 103 markers A–Z
Butyrate — frequently asked questions
What is Butyrate?
The primary short-chain fatty acid that fuels colon cells — the postbiotic your gut bacteria normally make from fiber, supplied directly.
What is the suggested dose of Butyrate?
As directed (tributyrin is better-absorbed and less odorous). This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Butyrate dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Butyrate?
Coach Cam sources Butyrate from vetted, top-rated brands on iHerb — use the buy link on this page.
Butyrate inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Butyrate is used for
Butyrate appears under 3 goals in the goal router.
Related Gut & Digestion supplements
Where this goes next
Butyrate is the gut-lining arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.